上述数据使用的会计准则为 NonUS_GAAP。$Santen Pharmaceutical (ADR) (SNPHY.US)$The financial report will be released on November 7th, investors are welcome to pay attention.
How was the performance before?
$Santen Pharmaceutical (ADR) (SNPHY.US)$2025/Q1 revenue of 74.771 billion yen, net income of 10.607 billion yen, earnings per share of 29.5 yen.
2024/Q2 revenue of 73.417 billion yen, net income of 8.862 billion yen, earnings per share of 24.52 yen.
The accounting standards used in the above data are NonUS_GAAP.
Futubull Reminder:
1. The accounting year of Hong Kong stocks and U.S. listed companies is not rigidly defined, and is completely decided by the company itself, so each financial report period can be the deadline for the company's annual report, without using the natural year as the financial year.
2. Generally, the company will hold a financial report meeting on the above-mentioned financial report release date or near the date. The company's management will then discuss and explain the latest quarterly financial data and operational situation with investors, analysts, media, etc., and communicate through offline meetings or online conference calls, etc.
Investors can participate through offline meetings or online conference calls.
